MGS-0039

MGS-0039 is a drug that is used in neuroscientific research, which acts as a potent and selective antagonist for group II of the metabotropic glutamate receptors (mGluR2/3).[1][2] It produces antidepressant and anxiolytic effects in animal studies,[3][4][5][6] and has been shown to boost release of dopamine and serotonin in specific brain areas.[7][8] Research has suggested this may occur through a similar mechanism as that suggested for the similarly glutamatergic drug ketamine.[9][10]

MGS-0039
Clinical data
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Identifiers
IUPAC name
  • (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H14Cl2NO5
Molar mass359.18 g·mol−1
3D model (JSmol)
SMILES
  • F[C@@]2(C(=O)O)[C@H]3[C@@](C(=O)O)(N)[C@H](OCc1ccc(Cl)c(Cl)c1)C[C@@H]23
InChI
  • InChI=1S/C15H14Cl2FNO5/c16-8-2-1-6(3-9(8)17)5-24-10-4-7-11(14(7,18)12(20)21)15(10,19)13(22)23/h1-3,7,10-11H,4-5,19H2,(H,20,21)(H,22,23)/t7-,10-,11+,14-,15+/m1/s1
  • Key:LFAGGDAZZKUVKO-JAGWWQSPSA-N

References
  1. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, et al. (March 2004). "MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity". Neuropharmacology. 46 (4): 457–67. doi:10.1016/j.neuropharm.2003.10.009. PMID 14975669. S2CID 40533560.
  2. Nakazato A, Sakagami K, Yasuhara A, Ohta H, Yoshikawa R, Itoh M, et al. (August 2004). "Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists". Journal of Medicinal Chemistry. 47 (18): 4570–87. doi:10.1021/jm0400294. PMID 15317467.
  3. Shimazaki T, Iijima M, Chaki S (October 2004). "Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test". European Journal of Pharmacology. 501 (1–3): 121–5. doi:10.1016/j.ejphar.2004.08.016. PMID 15464070.
  4. Yasuhara A, Nakamura M, Sakagami K, Shimazaki T, Yoshikawa R, Chaki S, et al. (June 2006). "Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential". Bioorganic & Medicinal Chemistry. 14 (12): 4193–207. doi:10.1016/j.bmc.2006.01.060. PMID 16487713.
  5. Yoshimizu T, Shimazaki T, Ito A, Chaki S (July 2006). "An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats". Psychopharmacology. 186 (4): 587–93. doi:10.1007/s00213-006-0390-7. PMID 16612616. S2CID 7801709.
  6. Stachowicz K, Wierońska J, Domin H, Chaki S, Pilc A (2011). "Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin- and GABA-dependent". Pharmacological Reports. 63 (4): 880–7. doi:10.1016/S1734-1140(11)70603-X. PMID 22001975.
  7. Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A (April 2005). "Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors". Neuroscience Letters. 378 (3): 131–4. doi:10.1016/j.neulet.2004.12.021. PMID 15781145. S2CID 26509964.
  8. Karasawa J, Yoshimizu T, Chaki S (January 2006). "A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell". Neuroscience Letters. 393 (2–3): 127–30. doi:10.1016/j.neulet.2005.09.058. PMID 16233956. S2CID 20736438.
  9. Pałucha-Poniewiera A, Wierońska JM, Brański P, Stachowicz K, Chaki S, Pilc A (December 2010). "On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039". Psychopharmacology. 212 (4): 523–35. doi:10.1007/s00213-010-1978-5. PMC 2981731. PMID 20703449.
  10. Koike H, Iijima M, Chaki S (December 2011). "Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists". Neuropharmacology. 61 (8): 1419–23. doi:10.1016/j.neuropharm.2011.08.034. PMID 21903115. S2CID 23923192.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.